Naloxone and its use in neonatal septic shock.
Current research suggests that the secretion of beta-endorphin from the pituitary gland may be associated with the refractory hypotension seen in patients with septic shock. Extensive animal research and a few clinical studies have demonstrated that naloxone, a narcotic antagonist, can increase MAP, cardiac output, and cardiac contractility and improve survival in victims of endotoxic shock. The ability of naloxone to improve MAP, however, appears to decrease with prolonged persistent hypotension (greater than eight hours). Studies also suggest that a synergistic effect exists between naloxone and the steroid methylprednisolone in improving the hemodynamics of these patients. In the future, naloxone may prove to be essential in the management of patients in the early stages of septic shock, but more complete clinical trials are warranted. It is imperative that nurses be involved in this type of clinical research.
Nash
P L
PL
D004509:Education, Nursing, Continuing; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D009270:Naloxone / Q000494:pharmacology / Q000627:therapeutic use*; D012772:Shock, Septic / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology; D001615:beta-Endorphin / Q000187:drug effects / Q000502:physiology
D009270:Naloxone; D001615:beta-Endorphin